NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $6.18 +0.03 (+0.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.10▼$6.2550-Day Range$4.91▼$6.5052-Week Range$3.30▼$6.75Volume357,346 shsAverage Volume792,983 shsMarket Capitalization$359.68 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Vanda Pharmaceuticals alerts: Email Address Vanda Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.0% Upside$11.00 Price TargetShort InterestHealthy5.06% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.99Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector151st out of 936 stocksPharmaceutical Preparations Industry61st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingVanda Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.06% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 2.45%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 3.3 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Vanda Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows7 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -77.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -77.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesJuly 26 at 9:19 AM | prnewswire.comVanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024July 21, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 1, 2024 | prnewswire.comFederal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and ApotexJune 26, 2024 | reuters.comFuture Pak withdraws offer to buy Vanda PharmaceuticalsJune 26, 2024 | businesswire.comFuture Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.June 20, 2024 | benzinga.comVanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionJune 19, 2024 | reuters.comVanda rejects Future Pak and Cycle Pharma's takeover offersJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 19, 2024 | prnewswire.comVanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its ShareholdersJune 13, 2024 | globenewswire.comGlobal Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%June 13, 2024 | prnewswire.comVanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakJune 13, 2024 | reuters.comFuture Pak raises cash portion of buyout offer for VandaJune 13, 2024 | businesswire.comFuture Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.June 10, 2024 | businesswire.comCIONIC Unveils Three New Centers of Excellence on the East Coast to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and NeuromodulationJune 10, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.June 6, 2024 | prnewswire.comVanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.May 30, 2024 | prnewswire.comVanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare ConferenceSee More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+78.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.51 million Net Margins-2.75% Pretax Margin-2.17% Return on Equity-0.90% Return on Assets-0.76% Debt Debt-to-Equity RatioN/A Current Ratio4.71 Quick Ratio4.69 Sales & Book Value Annual Sales$192.64 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$9.47 per share Price / Book0.65Miscellaneous Outstanding Shares58,200,000Free Float53,717,000Market Cap$359.68 million OptionableOptionable Beta0.75 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 64)Founder, President, CEO & Chairman of The Board Comp: $1.51MMr. Timothy Williams (Age 48)Senior VP, General Counsel & Secretary Comp: $724.38kMr. Joakim Wijkstrom (Age 58)Senior VP & Chief Marketing Officer Comp: $836.36kMr. Scott L. HowellChief People OfficerKey CompetitorsAkouosNASDAQ:AKUSGossamer BioNASDAQ:GOSSAlbireo PharmaNASDAQ:ALBOAnaptysBioNASDAQ:ANABDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 20,721 shares on 7/26/2024Ownership: 0.443%Allspring Global Investments Holdings LLCSold 9,043 shares on 7/26/2024Ownership: 0.260%Gladius Capital Management LPSold 3,179 shares on 7/19/2024Ownership: 0.011%Diversified Trust CoSold 50,645 shares on 7/16/2024Ownership: 0.020%SG Americas Securities LLCBought 10,822 shares on 7/12/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $4.22 at the beginning of 2024. Since then, VNDA stock has increased by 46.4% and is now trading at $6.18. View the best growth stocks for 2024 here. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.12. The biopharmaceutical company had revenue of $47.46 million for the quarter, compared to analyst estimates of $48.50 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 0.90% and a negative net margin of 2.75%. What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Vanda Pharmaceuticals' major shareholders? Top institutional investors of Vanda Pharmaceuticals include Profit Investment Management LLC (0.98%), Bank of New York Mellon Corp (0.44%), Allspring Global Investments Holdings LLC (0.26%) and Diversified Trust Co (0.02%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Kevin Patrick Moran, Joakim Wijkstrom, Timothy Williams, Richard W Dugan, Stephen Ray Mitchell and Aranthan Jones II. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL) and Sangamo Therapeutics (SGMO). This page (NASDAQ:VNDA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts